Convergence Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Convergence Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,728	Closed	-$270K	–	285
2020 Q4	$270K	Sell	1,728 -7,869	-82%	-$1.01M	0.14%	146
2020 Q3	$1.1M	Buy	9,597 +547	+6%	+$59K	0.38%	95
2020 Q2	$1.02M	Buy	+9,050	New	+$961K	0.35%	98
2019 Q4	–	Sell	-11,997	Closed	-$1.18M	–	337
2019 Q3	$1.18M	Buy	+11,997	New	+$1.35M	0.33%	112
2018 Q2	–	Sell	-575	Closed	-$64K	–	993
2018 Q1	$64K	Buy	+575	New	+$68.7K	0.01%	407
2014 Q4	–	Sell	-5,135	Closed	-$851K	–	439
2014 Q3	$851K	Sell	5,135 -3,238	-39%	-$532K	0.12%	262
2014 Q2	$1.31M	Buy	+8,373	New	+$1.32M	0.17%	189

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Convergence Investment Partners's ALXN Position: Q1 2021 in Review

Convergence Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,728 shares — an estimated $270K sold.

Convergence Investment Partners first reported a position in ALXN in Q2 2014 and held it in 7 quarters. The position peaked at $1.31M in Q2 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Convergence Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Convergence Investment Partners sold 1,728 Alexion Pharmaceuticals shares in Q1 2021, an estimated $270K.
Convergence Investment Partners first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 7 quarters.
Convergence Investment Partners's Alexion Pharmaceuticals position peaked at $1.31M in Q2 2014.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Convergence Investment Partners's 13F filing for Q1 2021, filed 30 Apr 2021.